Shaun Grady has global responsibility for Business Development Operations at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including licensing and partnering, M&A, externalisation and divestments.
Shaun was appointed to his current role in 2013. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010 – 13) and Vice President, Corporate Business Development (2006 – 10).
Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca Group PLC.
Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT) and later MedImmune and led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ – BMS Diabetes Alliance. More recently Shaun led the transaction team for AZ’s global ADC collaborations with Daichi Sankyo for Enhertu and subsequently DS -1062.
Shaun has led AZ’s recent Externalisation and divestment programme involving significant sell – side transactions with Pfizer, Aspen, Grunenthal, Cheplapharm, Atnahs, Juvise, Recordati and Covis.
Shaun is a Fellow in Entrepreneurship at Cambridge University Judge Business School and a Fellow Commoner of Lucy Cavendish College, Cambridge. Shaun is also Chairman of the the Board of Directors of Cambridge United Football Club, and a member of the Board at Cambridge Arts Theatre, Healx and Prostate Cancer Research Centre.
Based in Cambridge, Shaun enjoys rugby and soccer, and occasionally turns his hand to sports writing.